

Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera toward SARS-CoV-2 viruses

Sascha Hein, Marie-Luise Herrlein, Ines Mhedhbi, Daniela Bender, Vanessa Habberger, Nuka Benz, Jonathan Eisert, Julia Stingl, Michael Dreher, Doris Oberle, Jessica Schulze ... [See all authors](#) ✓

First published: 25 November 2021

<https://doi-org.bibliosan.clas.cineca.it/10.1111/all.15189>

Sascha Hein, Marie-Luise Herrlein and Ines Mhedhbi are equally contributed to this work.

Summary

Background

The mRNA vaccine BNT162b2 (Comirnaty, BioNTech/Pfizer) and the vaccine candidate CVnCoV (Curevac) each encode a stabilized spike protein of SARS-CoV2 as antigen but differ with respect to the nature of the mRNA (modified versus unmodified nucleotides) and the mRNA amount (30 µg versus 12 µg RNA). This study characterizes antisera elicited by these two vaccines in comparison to convalescent sera.

Methods

Sera from BNT162b2 vaccinated healthcare workers, and sera from participants of a phase I trial vaccinated with 2, 4, 6, 8, or 12 µg CVnCoV and convalescent sera from hospitalized patients were analyzed by ELISA, neutralization tests, surface plasmon resonance (SPR), and peptide arrays.

Results

BNT162b2-elicited sera and convalescent sera have a higher titer of spike-RBD-specific antibodies and neutralizing antibodies as compared to the CVnCoV-elicited sera. For all analyzed sera a reduction in binding and neutralizing antibodies was found for the lineage B.1.351 variant of concern. SPR analyses revealed that the CVnCoV-elicited sera have a lower fraction of slow-dissociating antibodies. Accordingly, the CVnCoV sera almost fail to compete with the spike-ACE2 interaction. The significance of common VOC mutations K417N, E484K, or N501Y focused on linear epitopes was analyzed using a

peptide array approach. The peptide arrays showed a strong difference between convalescent sera and vaccine-elicited sera. Specifically, the linear epitope at position N501 was affected by the mutation and elucidates the escape of viral variants to antibodies against this linear epitope.

Conclusion

These data reveal differences in titer, neutralizing capacity, and affinity of the antibodies between BNT162b2- and CVnCoV-elicited sera, which could contribute to the apparent differences in vaccine efficacy.

Abbreviations

Ab

antibody

Alfa

SARS-CoV-2 Alfa variant

Beta

SARS-CoV-2 Beta variant

BNT162b2

mRNA COVID-19 vaccine

COVID-19

coronavirus disease 2019

Ctrl

negative control sera

CVnCoV

mRNA COVID-19 vaccine

mRNA

messenger ribonucleic acid

RBD

receptor-binding domain

SARS-CoV-2

severe acute respiratory syndrome coronavirus 2

1 INTRODUCTION

Since its emergence in December 2019, infection by SARS-CoV-2 has caused on August 2021 (21.08. 2021) over 211 million cases of coronavirus disease 2019 (COVID-19) and more than 4.9 million deaths worldwide (source: COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at John Hopkins University (JHU)). Exceptional research efforts led to the rapid development of vaccines. Almost all vaccines are based on the viral spike protein (S) ¹. S is a trimeric glycoprotein which is located on the viral surface and mediates the interaction with the receptor angiotensin-converting enzyme 2 (ACE2) ^{2, 3}. Each S-monomer encompasses two domains, S1 and S2. These two domains mediate viral

binding to ACE2 and fusion with the host cell membrane, respectively. The receptor-binding domain (RBD) is located within S1 and represents a major target for neutralizing antibodies⁴. In the EU and in the US mRNA-based vaccines were the first approved vaccines. BNT162b2 (Comirnaty/Tozinameran, BioNTech/Pfizer) received a temporary emergency use authorization (EUA) in the UK and, subsequently, a series of approvals or authorizations for emergency use in Bahrain, Canada, Mexico, Saudi Arabia, and the USA. In Switzerland (19 December 2020) and the EU (21 December 2020), BNT162b2 received conditional market authorization for active immunization against COVID-19 for individuals 16 years of age and older⁵⁻⁷. The mRNA vaccine produced by Moderna obtained the conditional marked authorization in the EU in January 2021^{8,9}. A further vaccine candidate based on mRNA is developed by Curevac (CVnCoV)¹⁰. Although these three vaccines are all based on mRNA which encodes SARS-CoV-2 full-length spike protein (S-protein) locked in the prefusion conformation (no further viral proteins are encoded in contrast to a natural infection) and are applied in a two-dose regimen, there are some striking differences between them. CVnCoV is based on unmodified RNA. In contrast to this, the mRNA vaccines produced by BioNTech/Pfizer and Moderna are based on a modified mRNA harboring 1-methylpseudouridine instead of uridine. Moreover, the RNA amount per vaccine dose differs. In case of BNT162b2 30 µg and in case of the Moderna vaccine, 100 µg are used. CVnCoV contains 12 µg per dose¹¹. The analysis of the vaccine efficacy showed an efficacy of over 94% for BNT162b2 and Moderna in clinical trials toward symptomatic disease¹².

The final analysis of the pivotal phase 2b/3 HERALD three trial revealed that CVnCoV is 48% effective at staving off disease of any severity¹³⁻¹⁶. A higher efficacy of about 77% was observed for the group of 18–60-year-old individuals, if prevention of moderate or severe disease was considered endpoint. Although the emergence of novel variants during the trial might have affected the result it seems that there is a lower efficacy as compared to the mRNA vaccines from Moderna and BioNTech/Pfizer¹⁶.

Based on these data, this study aims to perform an analysis of sera derived from BNT162b2- or CVnCoV-vaccinated individuals and of convalescent sera with respect to their neutralizing titers, binding affinities to the spike RBD domain of wild-type SARS-CoV-2 and of variants of concern (VOCs) and to their interference with the ACE2/RBD interaction.

2 MATERIALS AND METHODS

2.1 Cell culture and virus strains

Vero E6 (ATCC® CRL-1586™) cells and HEK293T cells (ATCC CRL-3216™) were maintained in Dulbecco's modified Eagle's medium (DMEM, Sigma, Taufkirchen, Germany) with 10% FCS (Sigma, Taufkirchen, Germany), 1% penicillin/streptomycin, and 1% L-glutamine and incubated with 5% CO₂ at 37°C. The SARS-CoV-2 virus isolates used belonged to the Pangolin lineages B.1.1.7, B.1.351, and B.1.1.298. As an early isolate, the UVE/SARS-CoV-2/2020 /FR/702 (GenBank: MT777677.1; here named as MRS) was used provided by the EVAg.

2.2 RBD mutant generation

For mutagenesis, the *rbd* gene was subcloned from the pCAGGS-sRBD plasmid (Florian Kramer, Icahn School of Medicine at Mount Sinai; ¹⁷) into the expression pcDNA3.1(-)-plasmid (Thermo Fisher Scientific, Waltham, USA) with standard cloning procedures. The mutagenesis was performed by the QuikChange Site-Directed Mutagenesis with the PfuUltra High-Fidelity DNA Polymerase (Agilent, USA, Santa Clara) according to the manufacturer's protocol and the respective primer pair (Table [S1](#)). All generated plasmids (Table [S2](#)) were validated by sequencing.

2.3 Protein production and purification

HEK293T cells were grown in standard DMEM medium with 10% FCS. For transfection, 4.5×10^6 cells/150mm dish were seeded 6 h before. The transfection mix of 3 ml was prepared with by mixing 15 µg plasmid DNA in 1.5 ml PBD with 1.5 ml of PEI (60 µg/ml). 16h after transfection, the 30 ml fresh DMEM medium was added to the cells. The supernatant was harvest 72 h post transfection. A 5 ml Ni-NTA affinity chromatography column (Cytiva, Uppsala, Sweden) was used and equilibrated with 5 CV of wash puffer with a flow rate of 2 ml/min. After sterilfiltration, the supernatant was mixed 1:1 with wash buffer (40 mM imidazole in PBS, pH 8.0) and was used directly for purification. The column was washed with 15 CV of wash buffer, and the protein was eluted with 250 mM imidazole in PBS.

2.4 Plaque reduction neutralization test (PRNT50)

The plaque reduction neutralization test was performed in duplicate in the BSL-3 facility at PEI. 6×10^5 of Vero E6 cells per well were seeded to six-well plates (Geiner Bio-One, Kremsmünster, Austria) and incubated at 37°C for 24 h. The sera were 2-fold serially diluted (1:20 to 1:640) and incubated with 80 PFU of the early isolate (MRS) and the different SARS-CoV-2 variants in a total volume of 100 µl at 37°C for 1 h as described ¹⁸.

2.5 Sera

Sera from 35 health care workers receiving routine COVID-19 vaccination with BNT162b2 and sera from participants of a phase I study who were vaccinated with CVnCoV. A total of 12 negative control sera were collected from healthy PEI workers. 20 CVnCoV sera were preselected by the provider (Curevac AG Tuebingen, Germany (each two high and two low titer sera vaccinated with the following mRNA concentrations: 2, 4, 6, 8, or 12 µg). Convalescent sera were provided by the RWTH centralized Biomaterial Bank (RWTH cBMB) of the Medical Faculty of the RWTH Aachen University.

2.6 Ethics

The study (PEI-SARS-CoV-2) was approved by the local ethics committee (Ethik-Kommission, Landesärztekammer Hessen 60314 Frankfurt am Main) and written informed consent was obtained from all participants (2020-1664_2-evBO). Convalescent sera provided by the RWTH

Aachen University Hospital have been collected in a prospective study which was provided by the RWTHcBMB were was approved by the local ethics committee (Ethikvotum 206/09 der Ethikkommission der Medizinischen Fakultät der RWTH Aachen University), and the study was performed in accordance with the ethical standards laid down in the Declaration of Helsinki in its latest revision. The studies performed by Curevac are covered by Trial EudraCT 2020–001286–36; CEC Reference Number 433/2020AMG1, Ethik Kommission Universitätsklinikum Tübingen and CEC Reference Number BC-07807, Commissie voor medische Ethiek University Gent. The study was performed in accordance with the provisions of the Declaration of Helsinki and good clinical practice guidelines.

2.7 ELISA

50 µl purified antigen (4 µg/ml in PBS) was used to coat the 96-well microtiter plates (costar 3590, Corning Incorporated, Kennebunk, USA) over night at 4°C. The ELISA was performed in duplicate as described ¹⁷.

2.8 Peptide Microarray

The wild-type peptides and the mutation carrying peptides were synthesized with the MultiPep2 (Intavis AG, Tuebingen, Germany) according to the principle of Merrifield ¹⁹. Synthesized peptides and DMSO (Blank spots) were spotted onto adhesive foil (Lasertab LAT-34–747–1, Brady, Milwaukee, USA) in a format of 1.5 cm x 1.5 cm. Using a slide-spotting robot (Intavis AG, Tuebingen, Germany) peptides and DMSO (Blank spots) were immobilized in a duplicate on a cellulose membrane (Intavis AG, Tuebingen Germany) attached to a 15 mm x 15 mm slide. Peptide arrays were performed in duplicate according to a modified protocol form ²⁰. For detection, the arrays were incubated with goat anti-human IgG IRDye680 (LI-COR, Bad Homburg, Germany) diluted 1:10,000. The arrays were scanned with LI-COR Odyssey CLx (LI-COR, Bad Homburg, Germany). Scanned images were analyzed with the software Image Studio Lite (LI-COR, Bad Homburg, Germany) and fluorescence intensity (FI) values extracted. For analysis, the mean of the fluorescence intensity values and the Fold Change ($FC = (FI_{WT}/FI_{Mut}) - 1$); WT. vs. Mut) were calculated in R (Version 4.0.3, (The R Core Team; 2020)).

2.9 Surface Plasmon Resonance (SPR)

Characterization of the patient sera by surface plasmon resonance was performed using the Biacore T200 system (Cytiva, Uppsala, Sweden). The purified RBD variants were diluted 1:10 to reach a concentration of 20 µM in immobilization buffer (10 mM HEPES +0.05% Tween-20, pH 7.0) for immobilization on two CM5 sensor chips (Cytiva, Uppsala, Sweden). Final response levels of 6622 RU (B.1.1.7), 6227 RU (B.1.1.298), and 6039 RU (MRS) were obtained on chip 1 and 7811 RU (B.1.351), 6656 RU (E484K), and 7031.1 RU (MRS) on chip 2. On each chip, one flow-cell remained blank to allow for background subtraction. Before starting the run, all sera were diluted 1:20 in running buffer (10 mM HEPES pH 7.1, 3 mM EDTA, 150 mM NaCl +0,05% Tween) supplied with 10% NSB reducer (Cytiva, Uppsala, Sweden). After three

start-up cycles with negative serum to block unspecific binding, patient sera were applied with a contact time set to 180 s, followed by 180 s dissociation. As described by Ju et al., competition of the patient sera with ACE2-binding was examined by addition of ACE2 (Sino Biological, Jing Dongbei, China) for 60 s at a concentration of 0.1 μM ²¹. Subsequently, two regeneration steps were performed using 10 mM Gly-HCl pH 2.5 for 60 s and 30 s, respectively. Anti-His (Santa Cruz Biotechnology, Dallas, USA) as well as anti-RBD antibodies (Sino Biological, Peking, China) served as control samples at the beginning and end of each run as well as five times distributed evenly throughout the run.

To compensate for reduction of binding capacity of the surface over time, patient serum responses were adjusted for the anti-RBD controls using the Biacore T200 evaluation software (Cytiva, Uppsala, Sweden). In addition, results were normalized on the mean anti-His response to compensate different immobilization levels of the RBD variants. Responses of ACE2 binding were adjusted for anti-His controls, as no competition of the anti-His antibody with ACE2 binding was expected.

2.9.1 Statistical Analysis

Statistical analysis was performed with the software Prism 8 (GraphPad) by using the default setting. The analysis of the peptide arrays was performed with R (Version 4.0.3).

3 RESULTS

3.1 Decreased binding of vaccine-elicited and convalescent sera to the B.1.351-derived RBD

In order to characterize the immune response elicited by two different mRNA-based vaccines, we compared sera obtained from individuals vaccinated either with BNT162b2 or with CVnCoV (or fractional doses thereof) and convalescent sera by ELISA for detection of RBD-binding IgGs. For the ELISA, the RBD domains derived from an early isolate (MRS), from the cluster V (lineage B.1.1.298; containing the Y293F mutation in the RBD)-, from the B.1.1.7 (Alpha; containing the N501Y mutation in the RBD)- or from the B.1.351 (Beta; containing the K417N, E484K and N501Y mutations in the RBD)-variant were used as target antigen. Moreover, the RBD domain harboring the exclusively the E484K mutant was instrumental.

In case of the BNT162b2 vaccine, sera from a cohort of vaccinated health care workers were obtained, in case of the CVnCoV vaccine, a set of sera from participants of a phase I/II trial were provided by Curevac²². The participants of the phase I trial were vaccinated with 2, 4, 6, 8, or 12 μg . For each group sera with high and low titer were provided. Convalescent sera were from hospitalized patients who suffered from acute respiratory distress syndrome (ARDS) or had no ARDS (27 patients without ARDS and 13 patients with ARDS). For all tested antigens, the ELISA revealed a significant higher titers in case of sera derived from individuals vaccinated with the standard dose of BNT162b2 (30 μg) as compared to convalescent sera. The titer of sera obtained from CVnCoV-vaccinated individuals were

lower even if the full dose of CVnCoV (12 µg) was used for immunization and the “high titer” group was exclusively considered (Figure 1). When RBDs of different VOCs were used as target antigen, it was observed that sera derived from BNT162b2 vaccinated individuals contain a slightly reduced amount of binding antibodies in case of the B.1.1.7 variant and more pronounced if the RBD derived from the B.1.351 isolate was tested (Figure 1A, B). In case of the convalescent sera, binding is strongly reduced when RBDs derived from the B.1.351 variant or of the E484K mutant were used as antigen. The set of sera with a high titer derived from CVnCoV-vaccinated individuals showed a decreased binding to the variants as compared to the BNT162b2-derived sera. For the B.1.1.298 and B.1.351 variants, decreased binding as compared to the other variants was observed.




FIGURE 1

[Open in figure viewer](#) | [PowerPoint](#)

Antibody responses against different SARS-CoV-2 RBD proteins. A, Sera from either BNT162b2 (35 sera) or CVnCoV (20 sera) vaccinated individuals or convalescent sera (40 sera) were tested by ELISA using the purified RBD domain from the MRS virus, the B.1.1.7, the B.1.351, the B.1.1.293 variant, or the E484K mutant as immobilized antigen. B, CVnCoV sera from A subdivided into those previously classified as high titer and low titer. The all values measured in duplicate and normalized against the Anti-His coating control. Bars represent the geometric mean including the 95% confidence intervals. The red dot marked patient is immunosuppressed and not included in the statistical analysis. The different CVnCoV dose groups are colored as described in the figure. AU/ml: arbitrary unit per milliliter

Taken together, these data indicate that the analyzed sera differ with respect to their titer of binding antibodies and the impact of mutations in the RBD on the titer.

3.2 Reduced neutralization of VOCs

As the titer of binding antibodies does not automatically reflect the titer of neutralizing antibodies, plaque reduction tests (PRNT₅₀) were performed using the MRS isolate and the B.1.1.7 and B.1.351 variants (Figure 2A, B). The assays revealed for the convalescent sera and for the BNT162b2-elicited sera a high neutralization capacity, which is only slightly reduced in case of the B.1.1.7 isolate. However, a stronger reduction, especially in case of the convalescent sera, is observed in case of the B.1.351 isolate. For the CVnCoV-elicited

sera, the neutralizing capacity was lower as compared to the BNT162b2 and to the convalescent sera and does not strictly correlate with the amount of RNA used for vaccination and with the titer of binding antibodies as detected by ELISA. As compared to the MRS isolate, for both analyzed VOCs, a reduction in the neutralization capacity can be observed for the CVnCoV sera for all analyzed dose groups. Moreover, only the 12 μ g mRNA dose in the high titer group shows a neutralization effect against all SARS-CoV2 variants. (Figure 2B). These data indicate that BNT162b2- and CVnCoV-elicited sera differ with respect to their neutralizing capacity. For all analyzed sera groups, a significant impact on the neutralizing capacity against the B.1.351 variant was found.




FIGURE 2

[Open in figure viewer](#) | [PowerPoint](#)

Neutralization of SARS-CoV-2 variants. A, Plaque reduction neutralization titer of 21 BNT162b2- or 20 CVnCoV-vaccinated individuals against SARS-CoV-2, the B.1.1.7 variant and the B.1.351 variant. 11 convalescent sera were tested. B, CVnCoV sera from A subdivided into those previously classified as high titer and low titer. Neutralization is represented by the PRNT₅₀ (the 50% plaque reduction neutralization titer, the reciprocal of the 50% inhibitory dilution per serum). Bars represent the geometric mean including the 95% confidence intervals. The red dot marked patient is immunosuppressed and not included in the statistical analysis. The different CVnCoV dose groups are colored as described in the figure

3.3 BNT162b2-elicited sera have a higher proportion of slow-dissociating antibodies

For a more detailed characterization of the immune response, the stability of the antigen-antibody complexes was analyzed by surface plasmon resonance spectroscopy (Figure 3). The RBD domains (MRS isolate, B.1.1.298, B.1.1.7, B 1.351 variant or the mutant E484K) were immobilized. Based on the dissociation phase, half-lives of the antigen-antibody-complexes were calculated, and two fractions were defined: the fast-dissociating antibodies (low affinity antibodies) characterized by short half-life of the antigen-antibody complex (Figure 3A, B) and the slow-dissociating antibodies (high affinity antibodies) with longer half-lives of the antigen-antibody complexes (Figure 3C, D). In case of the BNT162b2-elicited sera, proportion of the fast-dissociating antibodies was bigger as compared to the sera obtained from the

CVnCoV vaccinations and to convalescent sera (Figure 3E, F). Moreover, within the slow fraction of the BNT162b2 sera, there is a major fraction of long-lived complexes while the majority of the complexes in the CVnCoV and convalescent sera have a shorter half-life.




FIGURE 3

[Open in figure viewer](#) | [PowerPoint](#)

Stability of the RBD-antibody complexes. Purified RBD proteins corresponding to the wild-type, B.1.1.298, the B.1.1.7, and the B.1.351 isolate, and E484K variants were immobilized on CM5 sensor chips. The SPR measurement was performed using a Biacore T200 system (see experimental section for details). Sera from 35 BNT162b2 and from 20 CVnCoV-vaccinated individuals and 40 convalescent sera were analyzed. A, Half-lives of the fast dissociating antibodies anti-RBD antibodies. C, Half-lives of the slow-dissociating antibodies anti-RBD antibodies. E, Calculated percentage of slow-dissociating antibodies. B, D and F CVnCoV sera from A, C and E subdivided into those previously classified as high titer and low titer. The different CVnCoV dose groups are colored as described in the figure. To determine the stability of the antigen-antibody complex, sera were applied with a contact time of 180 s followed by a dissociation time of 180 s. The calculation was performed in the Biacore T200 evaluation software using the equation describing a simultaneous dissociation of two independent populations. sd-AB: slow-dissociating antibodies anti-RBD antibodies

Altogether, the SPR analyses indicate that for the wild-type, the B.1.1.298 and the B.1.1.7 variant the BNT162b2-elicited sera contain a bigger amount of high-affinity antibodies as

compared to the CVnCoV-elicited and convalescent sera.

3.4 CVnCoV-induced sera fail to compete with the ACE2/RBD interaction in SPR analyses

To further characterize the relevance of the antigen-antibody complex, the impact of the vaccine-elicited or convalescent sera on the interaction of the RBD domain with ACE2 was studied by SPR as described in the Methods Section. For the interaction of wild-type RBD with insect-cell-derived ACE2, a steady-state K_D value of 189.5 nM was found (Figure 4A). The interaction of ACE2 with the RBD domain of the MRS isolate, the E484K mutant and the B.1.351 variant in the presence of vaccine-elicited or convalescent sera revealed that under these conditions almost all of the CVnCoV-elicited sera have a weak or no impact on the RBD-ACE2 interaction (Figure 4B). In contrast to this, almost all of the BNT162b2 sera and of the convalescent sera were capable of significantly interfere with the ACE2/RBD interaction. Here, the strongest inhibitory effect of ACE2 binding is observed when the MRS-derived RBD is used as ligand, a weaker effect found for the E484K mutant and for the B.1.351 variant. These results fit to the antigen-antibody complex stability data described above, showing that the CVnCoV sera contain a higher fraction of fast-dissociating antibodies and therefore have a lower potential to compete the ACE2/RBD interaction. Taken together, these data indicate in accordance to the affinity data that most of the BNT162b2-elicited sera and of the convalescent impair the binding of ACE2 to RBD, while most of the CvnCoV-elicited sera fail to exert a robust effect on the ACE2-RBD interaction under these assay conditions.




FIGURE 4

[Open in figure viewer](#) | [PowerPoint](#)

BNT162b2 and convalescent sera contain higher amounts of antibodies against the ACE2 interface of RBD. Purified RBD proteins corresponding to the wild-type, the B.1.351 isolate and E484K variant were immobilized on a CM5 sensor. The analysis was performed using a BiacoreT200 system. A, Kinetic properties of insect cell-derived ACE2 against the wild-type RBD. Serial 2-fold dilutions of ACE2 (starting with 750 nM) were injected. After an association of 200 s, the respective RUs were visualized and used for the calculation of steady-state affinity. ACE2-RBD K_D of 189.5 nM was calculated. Sera from 35 BNT162b2 and from 20 CVnCoV-vaccinated individuals and 40 convalescent sera were analyzed. B, SPR measurements were performed as shown in Figure 2. After the dissociation step of 180 s, ACE2 was

added for 60 s followed by a second dissociation time of 180 s. The ACE2 binding stability was calculated after 60 s and normalized against the ACE2 binding stability from the anti-His-Tag antibody (immobilization control; see experimental section for details). The red dot marked patient is immunosuppressed. The different CVnCoV dose groups are colored as described in the figure. Neg. ctrl: negative control sera; Con. Sera: convalescent sera

3.5 The pattern of linear epitopes recognized by vaccine-elicited and convalescent sera differs

Finally, the recognition of linear epitopes covering amino acids K417, E484, or N501 by the sera was analyzed by peptide arrays (Figure 5 and Figure S1). These amino acids were chosen as they are frequently mutated in a variety of SARS-CoV-2 variants. Quantification of the antibodies bound to these epitopes and visualization by the heatmap (Figure 5A) revealed that BNT162b2- and CVnCoV-elicited sera strongly recognize linear epitopes harboring K417, while the recognition by convalescent sera is detectable but less pronounced. Linear epitopes covering E484 are moderately recognized by the vaccine-elicited and convalescent sera. Linear epitopes containing N501 are better recognized by the vaccine-elicited sera than by the convalescent sera. Comparison of the binding to the wild-type sequence with the binding to the mutated sequence revealed that the K417N mutation has almost no effect on the binding of the analyzed vaccine-elicited sera and convalescent sera (Figure 5B). The E484K and especially the N501Y mutation affected the binding of convalescent sera to the corresponding linear epitopes but this effect was less pronounced compared to the effect on the CVnCoV- and BNT162b2 elicited sera. Especially in case of the N501Y mutation there was a strong decrease in the binding of BNT162b2- and CVnCoV-elicited sera (Figure 5C). This effect was more distinct for the BNT162b2-sera. (Figure 5B).




FIGURE 5

[Open in figure viewer](#) | [Download PowerPoint](#)

Linear epitopes are discriminated by mutation E484K and N501Y. A, Fluorescence intensities of recognized wild-type peptides. Sera from 34 BNT162b2 and from 20 CVnCoV-vaccinated individuals, 40 convalescent sera and three negative control sera were analyzed. B, Fold-change values of the fluorescence intensity of wild-type peptides compared with the respective mutated peptide (WT vs. Mut). As a threshold for possible epitope discrimination by the mutation, an FC

greater than 2 was set in at least two adjacent peptides. C, Peptide arrays of selected sera. Shown are the peptide arrays of three different sera and a Coomassie-stained array. In the sera BNT162b2-30 and BNT162b2-31 the influence of the mutation in the peptide array can be seen directly (white boxes). The right white boxes show the wild-type N501 peptides, the left boxes the mutation-bearing N501Y peptides. The negative serum shows no significant signal for any peptide. To rule out the possibility that the difference in intensity was due to a difference in the amount on peptide of the spots, 5 arrays were stained with Coomassie after each synthesis. No difference is detectable the Coomassie-stained array for the N501 and N501Y peptides. The peptide sequences are shown in Figure S1. Ctrl: negative control sera; F-Intensity: fluorescence intensity

These data indicate that sera elicited by the RNA vaccines BNT162b2 and CVnCoV strongly recognize linear epitopes encompassing K417 and less distinct N501. However, the binding to the linear epitope around aa417 is not significantly affected by the K417N mutation, while the E484K and the N501Y mutation caused a stronger decrease of the binding to these epitopes, especially in case of the BNT162b2-elicited sera.

4 DISCUSSION

The study characterizes the SARS-CoV-2 spike-RBD-specific humoral immune response elicited by two different mRNA vaccines (BNT162b2 and CVnCoV) and by convalescent sera. The analysis revealed that there is a variety of differences between the investigated sera. It has to be mentioned that most of the CVnCoV-elicited sera were derived from individuals vaccinated with doses lower than the finally selected 12 µg RNA, which was used in the phase III trials. However, published data from the phase I trial and our data indicate that there is only a minor impact of the dose on the titer of spike-specific IgG or on the neutralizing capacity after the second vaccination ²².

ELISAs using the wild-type RBD or RBD variants (B.1.1.7, B.1.351 B.1.1.298 or the point mutation E484K) revealed for the CVnCoV-elicited sera, even if 12 µg were used for immunization, a lower titer of binding IgGs as compared to the BNT162b2-elicited sera or to the majority of convalescent sera. This correlates with the data from the neutralization experiments that demonstrate a lower neutralizing capacity of the CVnCoV-elicited sera as compared to convalescent or BNT162b2-elicited sera.

Apart from the lower titer, the weaker binding of CVnCoV-elicited antibodies to the RBD as determined by SPR could be a relevant factor for the decreased neutralizing activity. In case of BNT162b2-elicited sera and convalescent sera, a higher fraction of highly stable antibody-RBD complexes was found. In contrast to SARS-CoV-2, the interaction of SARS-CoV-2 with ACE2 is characterized by high affinity ²³. In light of this, the weaker binding of RBD antibodies in case of the CVnCoV-elicited sera fail to inhibit the RBD-ACE2 interaction. This might be a relevant factor that contributes to the reduced neutralization capacity in vitro and the lower vaccine efficacy of CVnCoV in clinical trials as compared to BNT162b2 ^{13, 14}. In the meantime further variants of interest or variants of concern (B.1.617.2 (Delta), B.1.525

(Eta), Iota (B.1.526), B.1.617.1 (kappa), C.37 (Lambda)) emerged. As these variants were not circulating in the period when the efficacy data were generated they were not analyzed in this study. The data from the peptide arrays reveal that there are qualitative differences between the vaccine-elicited sera on the one hand and the convalescent sera on the other hand. While the vaccines studied here are based on a stabilized spike, the spike in the wild-type virus exists in a non-stabilized form and in a context with further structural proteins. This might affect the antigenicity and thereby the pattern of recognized linear epitopes by the analyzed sera.

CVnCoV-immunized hamsters evolve a protective immune response¹⁰. However, as compared to the 12 µg RNA used for the vaccination of humans, the 2 or 10 µg used for the hamsters represent an artificially high concentration. An interim analysis of the efficacy analysis revealed for the CVnCoV vaccine a significant lower vaccine effectiveness in comparison to BNT162b2^{13, 24}. For CVnCoV, the vaccine efficacy against symptomatic COVID-19 was approximately 48% in the overall study population and 53% in the 18–60 years of age subgroup. A higher efficacy of about 77% was observed in the prevention of moderate to severe disease for the group of 18–60-year-old individuals.

There might be a variety of factors contributing to this result. The study was performed under conditions in which especially the B.1.1.7 lineage and other variants were dominating among the circulating viruses. For the B.1.1.7 neutralization analyses and especially “real world” vaccine effectiveness, data revealed for BNT162b2 a slightly reduced but still high vaccine effectiveness of 93,4%²⁵. For the B.1.351 variant neutralization assays revealed a reduced but still robust neutralization capacity of BNT162b2-elicited sera²⁶. As the structure of the antigen used for both mRNA vaccines is comparable (all are based on a stabilized spike protein in the prefusion conformation), other factors could contribute to the lower titer and vaccine efficacy. As compared to BNT162b2 or mRNA-1273, which are based on modified RNA and are applied in amounts of 30 µg and 100 µg respectively, CVnCoV is based on unmodified RNA. The reactogenicity of unmodified RNA limits the amount of mRNA, which can be used for vaccination. The amount of RNA and their translation efficacy affect the amount of produced antigen. It can be speculated that modified RNA and unmodified RNA differ with respect to their half-life. Differences in the stability and in the amount of delivered mRNA might affect the persistence of spike protein production and the amount of spike protein. Apart from the effect on the titer, both parameters might have an impact on the immune response ie, by affecting the affinity maturation and the T helper cell²⁷. In light of this, attempts to increase the amount of antigen produced were started by development of a second generation of the vaccine (CV2CoV). Here, a higher amount of produced antigen is found that is expected to contribute to a higher vaccine effectiveness^{10, 28, 29}.

Taken together, analyses of antisera elicited by regular vaccination with BNT162b2 or by vaccination with different amounts of CVnCoV (2–12 µg) and of convalescent sera revealed that the two RNA vaccines that encode the same antigen (spike in the prefusion conformation) significantly differ with respect to the elicited humoral immune response.

Even for the 12 µg CVnCoV-vaccinated group, differences in the titer, neutralization capacity and stability of the antigen-antibody complex were observed as compared to BNT162b2. Although effectiveness of a RNA vaccine depends on more parameters than serological parameters, the lower titer and neutralizing activity, the high fraction of low affinity antibodies that fail to compete the neutralization of ACE2 binding could contribute to a decreased vaccine effectiveness of CVnCoV.

ACKNOWLEDGMENTS

We would like to thank Gert Carra, Robin Oliver Murra, Anett Stühler, and Gudrun Heins for their excellent technical support. We thank CureVac for providing and selecting the sera and constructive discussions. Barbara Schnierle and Florian Krammer kindly provided the expression plasmid pCAGGS-sRBD. Furthermore, we thank Anja Drescher and Vanya Uzunova from Cytiva for their kind support and constructive discussions regarding the SPR data. The publication was supported by the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 871029. This research was funded by grants from the Federal Ministry of Health (BMG) to EH (VARIPATH) and TW (IMS-SARS-CoV-2). Open Access funding enabled and organized by Projekt DEAL.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTION

SH, MLH, IM, DO, and EH designed the research. SH, MLH, IM, DB, VH, NB, JE JS, and CM performed experiments. CH, MD, and JCS collected the clinical material, JCS organized provision of the clinical samples. JS, CM, MB, and TW provided virus isolates. SH, MLH, IM, DB, and EH analyzed the data, SH, MLH, IM, and EH wrote the manuscript. All authors read the manuscript.

Supporting Information



Filename	Description
all15189-sup-0001-SupInfo.docx Word 2007 document , 201 KB	Supplementary Material

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

REFERENCES



1 Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang H. The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. *Front Immunol*. 2020; **11**: 576622.

[Crossref](#) | [Web of Science®](#) | [Google Scholar](#)

2 Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. *PLoS Pathog*. 2018; **14**: e1007236.

[Crossref](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

3 Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature*. 2020; **581**: 215- 220.

[Crossref](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

4 Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veersler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*. 2020; **180**: 1- 12.

[Crossref](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

5 Lamb YN. BNT162b2 mRNA COVID-19 Vaccine: First Approval. *Drugs*. 2021; **81**: 495- 501.

[Crossref](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

6 Carneiro DC, Sousa JD, Monteiro-Cunha JP. The COVID-19 vaccine development: A pandemic paradigm. *Virus Res*. 2021; **301**: 198454.

[Crossref](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

7 Vasireddy D, Atluri P, Malayala SV, Vanaparthi R, Mohan G. Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use. *J Clin Med Res*. 2021; **13**: 204- 213.

[Crossref](#) | [CAS](#) | [PubMed](#) | [Google Scholar](#)

8 Yan Y, Pang Y, Lyu Z, et al. The COVID-19 Vaccines: Recent Development, Challenges and Prospects. *Vaccines*. 2021; **9**: 1- 16.

[Crossref](#) | [CAS](#) | [Web of Science®](#) | [Google Scholar](#)

9 Wagner R, Meißner J, Grabski E, Sun Y, Vieths S, Hildt E. Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe. *Allergy*. 2021; 1- 11.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

10 Rauch S, Roth N, Schwendt K, Fotin-Mleczek M, Mueller SO, Petsch B. mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. *NPJ Vaccines*. 2021; **6**: 57.

[Crossref](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

11 Verbeke R, Lentacker I, de Smedt SC, Dewitte H. The dawn of mRNA vaccines: The COVID-19 case. *J Controlled Release*. 2021; **333**: 511- 520.

[Crossref](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

12 Schoenmaker L, Witzigmann D, Kulkarni JA, et al. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. *Int J Pharm*. 2021; **601**: 120586.

[Crossref](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

13 CureVac. CureVac Provides Update on Phase 2b_3 Trial of First-Generation COVID-19. CVnCoV. Curevac. 2021.

[Google Scholar](#)

14 Cromer D, Reynaldi A, Steain M, Triccas JA, Davenport MP, Khoury DS. Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC).; 2021.trial: medRxiv: the preprint server for health sciences

[Crossref](#) | [Google Scholar](#)

15 Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. *Nat Rev Drug Discovery*. 2021; **20**(11): 817– 838.

[Crossref](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

16 Kremsner PG, Guerrero RAA, Arana E, et al. Efficacy and Safety of the CVnCoV SARS-CoV-2 mRNA Vaccine Candidate: Results from Herald, a Phase 2b/3, Randomised, Observer-Blinded, Placebo-Controlled Clinical Trial in Ten Countries in Europe and Latin America. *SSRN Electronic Journal*. 2021; 1– 29.

[Google Scholar](#)

17 Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv: the preprint server for health sciences 2020.

[Google Scholar](#)

18 Case JB, Bailey AL, Kim AS, Chen RE, Diamond MS. Growth, detection, quantification, and inactivation of SARS-CoV-2. *Virology*. 2020; **548**: 39- 48.

[Crossref](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

19 Merrifield RB. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. *J Am Chem Soc*. 1963; **85**: 2149- 2154.

[Crossref](#) | [CAS](#) | [Web of Science®](#) | [Google Scholar](#)

20 Kühne Y, Reese G, Ballmer-Weber BK, et al. A Novel Multi-peptide Microarray for the Specific and Sensitive Mapping of Linear IgE-Binding Epitopes of Food Allergens. *Int Arch Allergy Immunol*. 2015; **166**: 213- 224.

[Crossref](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

21 Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*. 2020; **584**: 115- 119.

[Crossref](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

22 Kremsner PG, Mann P, Kroidl A, et al. Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial. *Wien Klin Wochenschr*. 2021; 1- 11.

[Web of Science®](#) | [Google Scholar](#)

23 Wang Q, Zhang Y, Wu L, et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. *Cell*. 2020; **181**: 894- 904.e9.

[Crossref](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

24 Gebre MS, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado NB, et al. Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates: bioRxiv: the preprint server for sciences, 2021.

[Google Scholar](#)

25 Bernal JL, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. *The New England Journal of Medicine*. 2021; **385**: 585- 594.

[Crossref](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

26 Hoffmann M, Hofmann-Winkler H, Krüger N, et al. SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. *Cell Rep*. 2021; **36**: 1- 9.

[Crossref](#) | [Web of Science®](#) | [Google Scholar](#)

27 Obst R, van Santen H-M, Mathis D, Benoist C. Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response. *J Exp Med*. 2005; **201**: 1555- 1565.

[Crossref](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

28 Roth N, Schön J, Hoffmann D, Thran M, Thess A, Mueller SO, et al. CV2CoV, an enhanced mRNA-based SARS-CoV-2 vaccine candidate, supports higher protein expression and improved immunogenicity in rats, 2021.

[Google Scholar](#)

29 Hoffmann D, Corleis B, Rauch S, Roth N, Mühe J, Halwe NJ, et al. CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2. *Nat Commun*. 2021; **12**(1).

[Crossref](#) | [Web of Science®](#) | [Google Scholar](#)

[Download PDF](#)

About Wiley Online Library

Privacy Policy

Terms of Use

Cookies

Accessibility

Publishing Policies

Help & Support

Contact Us

Training and Support

DMCA & Reporting Piracy

Opportunities

Subscription Agents

Advertisers & Corporate Partners

Connect with Wiley

The Wiley Network

Wiley Press Room

Copyright © 1999-2021 John Wiley & Sons, Inc. All rights reserved

Supplementary Information:

Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera towards SARS-CoV-2 viruses

Short title: mRNA vaccine-elicited sera against SARS-CoV2

Sascha Hein^{1*}, Marie-Luise Herrlein^{1*}, Ines Mhedhbi^{1*}, Daniela Bender¹, Vanessa Habberger¹, Nuka Benz¹, Jonathan Eisert¹, Julia Stingl³, Michael Dreher⁴, Doris Oberle², Jessica Schulze⁵, Christin Mache⁵ Matthias Budt⁵, Christoph Hildt⁶, Thorsten Wolff⁵, Eberhard Hildt¹

Affiliations:

1) Paul-Ehrlich-Institut, Department of Virology, Paul-Ehrlich Street 51-59, D-63225 Langen, Germany, 2) Paul-Ehrlich-Institut, Division of Pharmacovigilance, Paul-Ehrlich Street 51-59, D-63325 Langen, Germany, 3) University Hospital of RWTH Aachen, Institute of Clinical Pharmacology, Pauwelsstraße 30, D-52074 Aachen, Germany, 4) Department of Pneumology and Intensive Care Medicine, RWTH Aachen University Hospital, D-52074 Aachen, Germany, 5) Robert-Koch-Institut, Influenza and Other Respiratory Viruses, Seestraße 10, D-13353 Berlin, Germany. 6) Main-Kinzig-Kliniken, Herzbachweg 14, D-63571 Gelnhausen, Germany10, D-13353 Berlin, Germany.

Corresponding author Email: Eberhard.Hildt@pei.de

[* equal contribution](#)

Wild type peptides		Mutated peptides
EVRQIAPGQT GK IAD	K417N	EVRQIAPGQT GN IAD
IAPGQT GK IADYNYK		IAPGQT GN IADYNYK
QT GK IADYNYKYNYK		QT GN IADYNYKYNYK
YQAGSTPCNG VE GFN	E484K	YQAGSTPCNG VK GFN
STPCNG VE GFNCYFP		STPCNG VK GFNCYFP
NG VE GFNCYFPLQSY		NG VK GFNCYFPLQSY
FPLQSYGFQPT NG VG	N501Y	FPLQSYGFQPT Y GVG
SYGFQPT NG VGYPY		SYGFQPT Y GVGYPY
QPT NG VGYPYRVVV		QPT Y GVGYPYRVVV

Figure S1. Sequences of the synthesized peptides. For each region (K417, E484 and N501), three peptides were with an overlap of 10 amino acids are synthesized. In addition, for each WT peptide, the respective mutation-bearing peptide was synthesized. The key amino acids are shown in red. Neighboring amino acids are colored in green.

Table S1. Nucleotide primers used in this study.

Primer	Sequence 5'->3'
XbaI-SigSpike-F	ATAATCTAGAATGTTTCGTGTTTCTGGTGCTGC
XbaI-His-R	TTAATCTAGATTATTCAATGGTGATGGTGATG
K417N-QC-F	GCCCCTGGACAGACAGGCAATATCGCCGACTACAACTAC
K417N-QC-R	GTAGTTGTAGTCGGCGATATTGCCTGTCTGTCCAGGGGC
E484K-QC-F	GCACCCCTTGTAACGGCGTGAAAGGCTTCAACTGCTACTTC
E484K-QC-R	GAAGTAGCAGTTGAAGCCTTTCACGCCGTTACAAGGGGTGC
N501Y-QC-F	CGGCTTTCAGCCACATATGGCGTGGGCTATCAGC
N501Y-QC-R	GCTGATAGCCACGCCATATGTGGGCTGAAAGCCG
Y453F-QC-F	GGCGGCAACTACAATTACCTGTTTCGGCTGTTCCGGAAGTCCAATC
Y453F-QC-F	GATTGGACTTCCGGAACAGCCGAAACAGGTAATTGTAGTTGCCGCC

Table S2. Plasmids used in this study.

Primer	Properties	Source
pcDNA3.1(-)	Mammalian expression vector	Thermo Scientific, USA, Waltham
pcDNA3.1(-)-SCov2-RBD	Expression and production of the His-tagged SARS-CoV-2 RBD	This study
pcDNA3.1(-)-SCov2-RBD-N501Y	Expression and production of the His-tagged SARS-CoV-2 B.1.1.7 (Alpha)-Variant RBD. Containing the N501Y mutation.	This study
pcDNA3.1(-)-SCov2-RBD-B.1.351	Expression and production of the His-tagged SARS-CoV-2 B.1.351 (Beta)-Variant RBD. Containing the K417N, E484K and N501Y mutations.	This study
pcDNA3.1(-)-SCov2-RBD-, B.1.1.298	Expression and production of the His-tagged SARS-CoV-2 B.1.1.298 (Cluster 5)-Variant RBD. Containing the Y293F mutation.	This study
pcDNA3.1(-)-SCov2-RBD-, E484K	Expression and production of the His-tagged SARS-CoV-2 E484K Variant RBD. Containing the E484K mutation.	This study
pCAGGS-sRBD	Expression and production of the His-tagged SARS-CoV-2 RBD	Amanat et al. 2020

Amanat, Fatima; Stadlbauer, Daniel; Strohmeier, Shirin; Nguyen, Thi H. O.; Chromikova, Veronika; McMahon, Meagan et al. (2020): A serological assay to detect SARS-CoV-2 seroconversion in humans. In: *medRxiv : the preprint server for health sciences*. DOI: 10.1101/2020.03.17.20037713.